Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GOAL.MD vs Ilant Health

GOAL.MD
Graded #142

Higher grade

vs+11.799999999999997
Ilant Health
Graded #407

Lower grade

The verdict

GOAL.MD takes it — 68.6/100 to 56.8/100.

GOAL.MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GOAL.MD is a St. Louis-based telehealth platform offering compounded semaglutide alongside brand-name bridges to Ozempic, Wegovy, and Zepbound. Its standout is a manual-renewal model — no auto-billing

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGOAL.MD +20
65
45
Dose & formulationGOAL.MD +46
86
40
Clinical oversightIlant Health +15
68
83
Labs & monitoringIlant Health +8
53
61
FulfillmentGOAL.MD +15
77
62
Contract termsEven
55
55
GOAL.MD · left barIlant Health · right bar

The numbers

MetricGOAL.MDIlant Health
WeighScore68.6/10056.8/100
GradeCC
Scorecard rank#142#407
Semaglutide$179/moNot disclosed
Tirzepatide$249/mo (starting dose, compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
GOAL.MD

Graded #142 · C

Strengths

  • Transparent dose-tiered pricing on brand pens
  • LegitScript Certified
  • Manual-renewal model — no surprise auto-billing
  • Free nutrition coach included
  • BBB A+ rating since 2021

Where it loses points

  • No named compounding pharmacy partner
  • Co-founder and chief physician has a 2016 federal guilty plea for distributing misbranded HGH and a (reinstated) license revocation
  • No URAC or PCAB pharmacy accreditation
Ilant Health

Graded #407 · C

Strengths

  • Value-based, outcomes-driven obesity care model
  • Includes GLP-1 medications with transparent drug pricing for sponsors
  • Care team of board-certified obesity providers and behavioral specialists
  • Dietitians and peer navigators support adherence
  • Data-driven stratification targets the right interventions

Where it loses points

  • Distributed via employers and health plans, not direct cash-pay
  • Individuals generally cannot enroll without sponsor coverage
  • No public consumer pricing for GLP-1
  • Access gated behind organizational buyers
  • Not suited to consumers wanting direct-to-door GLP-1

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard